Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First-in-Human trial launches for Custom-Built cancer treatment

NCT ID NCT07196579

Summary

This early-stage study is testing a new, personalized cell therapy called KXV01 for people with advanced solid tumors that have not responded to standard treatments. The therapy involves collecting a patient's own immune cells, genetically modifying them to better target their specific cancer, and then infusing them back. The main goals are to check the safety of different doses and see if the treatment shows any early signs of helping to control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.